feasibility of sequential treatment with cd19-targeted agents in patients with lbcl
Published 1 year ago • 111 plays • Length 2:26Download video MP4
Download video MP3
Similar videos
-
14:25
an overview of novel innovative treatments for patients with von willebrand disease
-
1:34
feasibility of the ipss-m in cmml
-
2:19
feasibility of biomarker-driven strategy in high-risk lbcl: final results from nordic phase ii study
-
1:41
using cytogenetics to improve the diagnosis and prognosis of mds & to predict response to treatment
-
6:24
indiko biochemistry analyzer demonstration
-
12:05
how to clean/change biobase hematology valves
-
26:46
webinar recording | technology advances in hematology testing | sparrc 2021 by srmc | mindray india
-
2:50
outcomes of delaying car-t infusion after lymphodepleting chemotherapy in patients with lbcl
-
1:33
sequencing and the management of adverse events when administering bispecifics for myeloma
-
4:45
safety and efficacy of obe-cel in r/r adult b-all: results of the pivotal felix study
-
4:48
an insight into the management of cytopenias in mf
-
2:45
the value of axi-cel as a second-line treatment in r/r lbcl
-
2:34
ruby & edithal trials: evaluating the safety and efficacy of edit-301 in scd & thalassemia
-
3:31
a summary of the prognostic factors that can influence the outcomes of anti-cd19 car-t in r/r dlbcl
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
0:39
selecting patients with scd for allosct
-
1:22
managing cytopenias following jak inhibitor treatment & achieving true disease modification in mf
-
1:24
mm-6 study: in-class transition to a regimen of ixazomib, lenalidomide, & dexamethasone for myeloma
-
0:45
difference between quality of life & patient-reported outcomes
-
2:41
an overview of the latest advances in hematology